Paylocity Holding Corporation delivered its fourth consecutive quarterly earnings beat, driven by durable revenue growth and expanding its client base. AI-driven product innovation, including the ...
As federal credit becomes increasingly utilized, federal agencies need a framework to quantify policy risk and create a common language to balance strategic priorities with financial risks.
Q4 2026 Earnings Call August 12, 2026 4:30 PM EDTCompany ParticipantsAhmed Sami Badri - Head of Investor Relations ...
Good missions don’t automatically become good results. Seven self-imposed burdens most often separate the two, and senior leaders can dismantle them.
Current company-specific hook: its quarterly update made battery-storage software and project execution a current energy theme. The central reader questions concern project delivery and software value ...
Current company-specific hook: its quarterly report sharpened attention on oncology pipeline execution. The central reader questions concern clinical evidence and regulatory planning and commercial ...
Employee monitoring software has been around for years. What's changed is how much it can do — and how much scrutiny companies face when they deploy it. Take TD Bank, for example, which made headlines ...
Marketing Week’s weekly round-up of the technology stories that impact the marketing sector: from AI to martech, regulation to public perceptions.
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, ...
The Business & Financial Times on MSN
When wives migrate: Emotional impacts and coping strategies of left-behind husbands in the Wa West District, Ghana
Please keep comments respectful. Use plain English for our global readership and avoid using phrasing that could be misinterpreted as offensive. By commenting, you agree to abide by our community ...
Pharvaris N.V.: Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results